Cdh4
- Known as:
- Cdh4
- Catalog number:
- 045386A
- Product Quantity:
- 250ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- Cdh4
Related genes to: Cdh4
- Gene:
- CDH4 NIH gene
- Name:
- cadherin 4
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 20q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-11
- Date modifiied:
- 2016-10-05
Related products to: Cdh4
Bovine Cadherin-4(CDH4) ELISA kitCadherin-4,CDH4,Chicken,Gallus gallus,R-CAD,R-cadherin,Retinal cadherinCadherin-4,CDH4,Homo sapiens,Human,R-CAD,R-cadherin,Retinal cadherinCadherin-4,Cdh4,Mouse,Mus musculus,R-CAD,R-cadherin,Retinal cadherinCadherin-4,Cdh4,Rat,Rattus norvegicus,R-CAD,R-cadherin,Retinal cadherinCadherin_4 _ CDH4 _ R_CAD AntibodyCadherin_4 _ CDH4 _ R_CAD Antibody (Antigen Affinity Purified)Canine Cadherin-4(CDH4) ELISA kitCanine Cadherin-4(CDH4) ELISA kitCDH26 Gene cadherin 26CDH4 (Human) Recombinant Protein (Q01)CDH4 3&_39;UTR Lenti-reporter-Luc VectorCDH4 antibodyCDH4 antibodyCDH4 antibody Related articles to: Cdh4
- Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), with hypophysitis being a serious endocrine toxicity that often requires hormone replacement and poses a risk of adrenal crisis. Biomarkers for predicting ICI-induced hypophysitis are lacking. - Source: PubMed
Publication date: 2026/06/08
Zheng YuanyuanChen YizhenLin WeiMin Le - To develop a personalized neoantigen therapy strategy for microsatellite stability (MSS)-advanced colorectal cancer (CRC), neoantigens from collected human CRC samples were screened, and the feasibility and effectiveness of these neoantigens in treating CRC were explored. Whole-exome sequencing and transcriptome sequencing were performed to identify somatic mutations, RNA expression, and human leukocyte antigen alleles. Based on these data, neoantigen candidates were predicted, and their immunogenicity was evaluated. Selected neoantigens from patients elicited enhanced T-cell responses in CRC peripheral blood lymphocytes. Mutated peptides SOX9-V144M, ZNF169-A275S, CDH4-V456M, NIM1K-T66M, and MAP3K9-R1008Q were more effective than nonmutated ones in Patient 1. Vaccination with mutant peptides ZNF169-A275S and CDH4-V456M inhibited tumor growth in an autologous humanized CRC mouse model. Highly immunogenic neoantigens are strong candidates for personalized cancer therapy, showing promise for translating into effective treatments for CRC patients with advanced disease. - Source: PubMed
Publication date: 2026/05/04
Li DajiangShen WenjingYang SiyuLiu HongmeiTan XiaoHe XinrongHao JingchaoYin Xinqiang - Sheep production contributes to a secure and diverse food and fibre supply in the United States, with growing ethnic diversity strengthening demand. Katahdin is a composite hair-type sheep breed developed in the United States that has become the most popular breed in many regions of the country and the first one to have genomic selection implemented in its breeding program. Therefore, the main objectives of this study were to estimate variance components of reproductive traits, including number of lambs born (NLB), number of lambs weaned (NLW), age at first lambing (AFL), and interval from first to second lambing (LI), in Katahdin sheep using the AIREML method and the single-step Genomic Best Linear Unbiased Prediction (ssGBLUP) approach, and to identify genomic regions and candidate genes associated with these traits. The datasets used consisted of 127,536 animals in the pedigree, phenotypic records of 56,128 parities from 24,067 ewes, and genomic data from 10,032 animals with 30,308 single-nucleotide polymorphisms (SNP) after quality control. Analyses were performed using the BLUPF90 family of programs. We observed low heritability estimates for all studied traits (0.09 ± 0.00 for NLB, 0.08 ± 0.00 for NLW, 0.09 ± 0.01 for AFL, and 0.08 ± 0.01 for LI). The genetic correlations between the traits ranged from 0.17 ± 0.02 (AFL and LI) to 0.79 ± 0.02 (NLB and NLW). All traits were found to be highly polygenic with all 14 significant SNP on eight (OAR) chromosomes (3, 6, 7, 8, 9, 12, 13, and 15) having small effects on the total variability on the traits. These SNP were located near or within 18 candidate genes: four genes associated with NLB (AAK1, GFPT1, SLC23A2, and GDAP1), four with NLW (ARHGAP18, TTLL2, UNC93A, and GPR31), six with AFL (NAP1L5, FAM13A, HS3ST1, CCDC181, NME7, and BLZF1), and four with LI (TAF4, CDH4, CADM1, and SEL1L). These candidate genes have been previously associated with fertility, embryonic development, growth, disease resistance, and climatic adaptation traits. Our findings indicate that fertility and reproduction traits in Katahdin sheep can be improved through direct genetic selection. Genetic improvement for these traits will benefit from genomic selection as more accurate estimates of breeding values for selection candidates can be obtained at a younger age. Although the studied traits are influenced by a complex interplay of genetic and environmental factors, the candidate genes identified enabled a better understanding of the biological mechanisms underlying reproductive performance in Katahdin sheep. - Source: PubMed
Publication date: 2026/03/30
Ospina Alejandra ToroLewis Ronald MFreking Bradley ABurke Joan MMurphy Thomas WWilson Carrie SBrito Luiz F - : As a treatment, fluoropyrimidines are often associated with early moderate-to-severe toxicity. Although pre-emptive genotyping enables genotype-guided dosing, significant adverse events still occur in patients classified as wild-type (WT). The aim of this study was to identify variants and evaluate the contributions of , , and variants to fluoropyrimidine toxicity. : A total of 256 European ancestry patients (aged ≥ 18 years, had completed ≥6 cycles of chemotherapy, and were WT for the variants routinely tested for) underwent genotyping for , , and variants, and full exon sequencing was performed in 56 of these patients. Toxicity was defined as fluoropyrimidine-related adverse events requiring a dose reduction. Multivariable models were adjusted for sex, fluoropyrimidine type, and the Charlson Comorbidity Index, and time-to-event was assessed using the Kaplan-Meier/Cox proportional hazards models. : A subgroup of 117 patients experienced toxicity requiring a dose reduction. The most frequent events were asthenia, gastrointestinal toxicity, hand-foot syndrome, and haematological toxicity. The rs2612091 C allele was associated with fluoropyrimidine withdrawal and a shorter time to dose reduction. In the patients treated with 5-fluorouracil, rs11280056 was associated with toxicity. exon sequencing identified thirteen variants, nine of which were more prevalent in the toxicity group. These included a canonical splice site (c.150+1G>A) and a stop-gained (c.1863G>A) variant, which is predicted to result in loss of function. : In real-world practice, despite undergoing standard genotyping, WT patients receiving a full dose of fluoropyrimidines develop clinically relevant toxicity. The presence of rare variants and associated genes ( and ) suggests that broader, prospectively validated pharmacogenetic strategies may improve toxicity prevention. - Source: PubMed
Publication date: 2026/03/11
Rodríguez-García MaríaSalvador-Martín SaraRojas Piedra Mariam StephanieBravo AdriánVidal MaríaFigueras Gutierrez CarolinaMaurel JoanLópez-Fernández Luis ABrunet Mercè - BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of childbearing age. In addition, it is a heterogeneous disease with numerous etiologies, multiple levels, and uneven manifestation. In patients with PCOS, the number of antral follicles is abnormally increased. Several studies indicate and preliminarily support that Hippo pathway abnormalities may contribute to PCOS development by promoting excessive antral follicle proliferation. Moreover, the key Hippo pathway effector, Yes-associated protein 1 (YAP1), contributes to PCOS susceptibility. Furthermore, dysfunction of ovaries in patients with PCOS leads to irregular granulosa cell (GC) growth, which can affect ovulation and cause infertility. Nevertheless, few studies have investigated the key mechanism regulating Hippo activation in PCOS. METHODS: Hippo-associated gene sets and publicly available sequencing databases were used to screen potential PCOS-driving genes, and cadherin 4 (CDH4, R-cadherin) was found to exhibit abnormally high expression in ovarian granulosa cells. Functional studies were conducted to investigate the effects of CDH4 inhibition on PCOS-related ovarian function. RESULTS: A lower CDH4 level ameliorated ovarian function in patients with PCOS by decreasing chronic inflammation and modulating mitochondrial function and apoptosis in GCs. Mechanistically, CDH4 interacts with UBA1 and RBMX, increasing the ubiquitin-dependent degradation of RBMX and finally resulting in the transcriptional activation of YAP1. These results highlight the pivotal role of CDH4 in PCOS, which is achieved through the regulation of the Hippo–YAP1 signaling axis. CONCLUSIONS: This study demonstrates that CDH4 plays a pivotal role in PCOS pathogenesis by regulating the Hippo–YAP1 signaling axis. The finding that reduced CDH4 could enhance the prognosis of individuals with PCOS by regulating ovarian GC activity could potentially inform novel treatment strategies. - Source: PubMed
Publication date: 2026/03/25
Xu NingYu BoLi YingyingYang YuxiWang YalongFang LinglingWu HongliangLuan YingyiYin Chenghong